KIT and acute myeloid leukemia: The patient, with a previously known t(8;21)(q22;q22.1) AML and found at relapse to carry an activating mutation of c-KIT, received targeted therapy with imatinib; the total peripheral white blood cell count normalized and the blast count significantly decreased, allowing a sustained control of disease for ~9 months until imatinib was discontinued due to toxicity.